The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
External validation of a tumor derived 5-gene prognostic signature (OncoDefender-CRC) for recurrence (R) of stages I/II colorectal cancer (CRC).
P. F. Lenehan
Employment or Leadership Position - Everist Genomics
Stock Ownership - Everist Genomics
L. A. Boardman
Research Funding - Everist Genomics
D. W. Fry
Employment or Leadership Position - Everist Genomics
Stock Ownership - Everist Genomics
E. R. Heyman
Consultant or Advisory Role - Everist Genomics
J. Ohrnberger
Employment or Leadership Position - Everist Genomics
Stock Ownership - Everist Genomics
W. P. Worzel
Employment or Leadership Position - Everist Genomics
Stock Ownership - Everist Genomics